• Alessandra Fabi, Luca Moscetti, Mariangela Ciccarese, Miriam Caramanti, Nello Salesi, Nicla La Verde, Michelangelo Russillo, Daniele Generali, Giuseppina Scandurra, Sabrina Vari, Umberto Pacetti, Francesco Cognetti, and Diana Giannarelli.
• Department of Medical Oncology, Regina Elena National Cancer Institute, Rome, Italy.
• Future Oncol. 2015 Jan 1; 11 (3): 431-8.

AimThis multicenter study describes the effectiveness of eribulin in current practice.Patients & MethodsIn total, 78 patients with advanced metastatic breast cancer, previously treated with two or more chemotherapy lines were enrolled.ResultsThe median duration of response and disease stability were 7.5 (5.4-9.5) and 8.9 (6.2-11.6) months, respectively, with a clinical benefit (CB) at 6 months in 41% of patients. CB in visceral and nonvisceral metastases were 72.7 and 88.9%, respectively. Eribulin was active also in brain metastases, with 47% CB. The activity was shown in all biological subtypes. Toxicities were manageable.ConclusionOur study confirms the effectiveness of eribulin mesylate in the treatment of patients with metastatic breast cancer and two or more lines of chemotherapy, in particular in the good disease control at the different metastatic sites.

34 keywords...

hide…